Published in final edited form as:

Org Lett. 2015 April 17; 17(8): 2018–2021. doi:10.1021/acs.orglett.5b00780.

Scalable Synthesis of Fmoc-Protected GalNAc-Threonine Amino Acid and T_N Antigen via Nickel Catalysis

Fei Yu[†], Matthew S. McConnell[†], and Hien M. Nguyen^{*}

Department of Chemistry, University of Iowa, Iowa City, Iowa 52242, United States

Abstract

The highly α -selective and scalable synthesis of the Fmoc-protected GalNAc-threonine amino acid and T_N antigen in gram scale (0.5 – 1 gram), is described. The challenging 1,2-*cis*-2-amino glycosidic bond is addressed through a coupling of threonine units with C(2)-*N*-*ortho*-(trifluoromethyl)benzylidenamino trihaloacetimidate donors mediated by Ni(4-F-PhCN)₄(OTf)₂. The desired 1,2-*cis*-2-amino glycoside was obtained in 66% (3.77 g) with α -only selectivity and subsequently transformed into the Fmoc-protected GalNAc-threonine and T_N antigen. This operationally simple procedure no longer requires utilization of the commonly used C(2)-azido donors and overcomes many of the limitations associated with the synthesis of 1,2-*cis* linkage.

Graphical abstract

Protein glycosylation can be generally divided into two major classes: *N*-linked and *O*-linked. In *N*-linked glycoproteins, an *N*-acetyl-glucosamine (GlcNAc) unit is β -linked to the amide nitrogen of an asparagine amino acid side chain.¹ In *O*-linked glycoproteins, an *N*-acetyl-galactosamine (GalNAc) unit is α -linked to the hydroxyl group of serine or threonine to generate a core structure **1** (Figure 1), commonly referred to as the T_N antigen.² Branching of this core structure **1** can take place at the C(3)- and/or C(6)-hydroxyl groups of GalNAc to give rise to a diverse array of structural motifs (e.g. TF antigen **2** and ST_N antigen **3**, Figure 1). These antigens are widely distributed on cell-surface mucin glycoproteins, which participate in cell adhesion events associated with cancer metastasis.³ The T_N antigen **1**, in particular, has been found to be highly expressed by mucins on most epithelial cancers.⁴ As a result, this T_N antigen has been investigated extensively as a biomarker and a therapeutic target for cancer vaccine therapy.⁵

^{*}Corresponding Author: Tel: +1-319-384-1887. hien-nguyen@uiowa.edu.

[†]Author Contributions

The authors contribute equally to the present work.

Supporting Information

Experimental procedures, ¹H and ¹³C NMR spectra, and characterization data of all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Notes

The authors declare no competing financial interest.

In the development of cancer vaccines, well-defined and pure T_N antigen as a single tumor antigen or as a component of a polyvalent vaccine is required. However, acquiring adequate amounts of T_N antigen from natural sources in homogenous form is challenging. In many cases, high purity T_N antigen can only be obtained by chemical and/or enzymatic synthesis.⁶ In the chemical synthesis strategy, C(2)-azido donors are the most commonly used substrates for generating the T_N antigen. Early work utilized a C(2)-azido halo donor **4** (Scheme 1) in the presence of the reagent combination of Ag₂CO₃ and AgClO₄ as a promoter to ensure α -selectivity (α : β = 4:1) in the glycosylation reaction.⁷ Another efficient synthesis of T_N antigen employed a C(2)-azido thioglycoside donor **5** (Scheme 1), and the Ph₂SO/Tf₂O system is employed to promote α -glycosylation reaction.⁸ Compound **7** was further converted into Fmoc-protected GalNAc-threonine amino acid **8** (2 steps, for use in the production of full-length glycosylated proteins) and T_N antigen **1** (3 steps). A number of efficient strategies were subsequently developed for generating glycopeptides containing the T_N antigen moiety.^{9,10}

Both glycosyl amino acid **8** and T_N antigen (**1**) are readily available, but they are expensive to purchase (**8**: \$303.50/25 mg and **1**: \$250/mg from Sigma-Aldrich). Although high purity T_N antigen can be chemically prepared, it cannot be easily and reproducibly obtained in large quantities. Most of existing glycosylation procedures require stoichiometric amounts of the activating agents to sufficiently activate donors, resulting in excessive waste materials.^{7–9} Some of these reagents can be air- and moisture-sensitive (e.g. Ph₂SO/Tf₂O)⁸ and potentially explosive (e.g. AgClO₄).⁹ In addition, the synthesis of the commonly used C(2)-azido donors **4** and **5** (Scheme 1) is not trivial. Lemieux's azidonitration method for preparing **4** and **5** is not very diastereoselective,¹¹ depending on the nature of the protecting groups on glycal starting material.¹² Alternatively, diazotransfer reaction can be utilized to prepare donors **4** and **5** through direct conversion of galactosamine by the action of either trifluoromethanesulfonyl azide or imidazole-1-sulfonyl azide,¹³ which are potentially explosive reagents. Although the diazotransfer method is frequently used for preparing **4** and **5**, it is unlikely to be suitable for large scale synthesis.¹⁴ Herein, we report a scalable and reproducible protocol for the synthesis of the glycosyl amino acid **8** and T_N antigen (**1**) via nickel-mediated α -glycosylation of threonine amino acids with C(2)-*N-ortho*-(trifluoromethyl)benzylidenamino trihaloacetimidate donors. This operationally simple procedure no longer requires the utilization of C(2)-azido glycosyl donors and is suitable for a gram-scale synthesis of **1** and **8**.

In recent years, our group has introduced nickel-catalyzed α -stereoselective glycosylation reaction as a general platform for preparations of a variety of 1,2-*cis*-2-amino glycosides.¹⁵ Additionally, we have illustrated that Ni(4-F-PhCN)₄(OTf)₂ effectively promoted a coupling of Cbz-protected threonine residue **10** with C(2)-*para*-(trifluoromethyl)benzylidenamino trichloroacetimidate donor **9** to afford glycosyl amino acid **11** (Scheme 2a) in 81% yield with α : β = 15:1.^{15b} We postulated that an analogous nickel-catalyzed α -selective coupling would be possible with Fmoc-protected amino acid **13** (Scheme 2b). Of two standard methods for the solid-phase peptide synthesis (SPPS) of glycopeptides containing T_N antigen unit, Fmoc-based chemistry is more utilized than Boc-based chemistry.^{1b} Unfortunately, employing 5 mol% of Ni(4-F-PhCN)₄(OTf)₂ to promote the coupling of **13**

with donor **9** only resulted in a 32% yield of **14** (Scheme 2b) with $\alpha:\beta = 2:1$. Alternatively, use of C(2)-*N*-*ortho*-(trifluoromethyl)benzylidenamino donor **12** (Scheme 1b) improved both the yield (32% $\rightarrow$ 80%) and α -selectivity ($\alpha:\beta = 2:1 \rightarrow 7:1$). Although α -trichloroacetimidate donor **12** acted as an effective donor, it was a minor anomer resulting from the reaction of hemiacetal with Cl_3CCN and DBU ($\alpha:\beta = 1:3$). Unfortunately, reaction of β -anomer of **12** with **13** resulted in no reaction.¹⁶

On the basis of our recent successful results with the use of *N*-phenyl trifluoroacetimidates as effective donors,^{15d-f} we hypothesize that triacetyl galactosamine donor **16** (Scheme 3), bearing the C(2)-*N*-*ortho*-(trifluoromethyl)benzylidene group, is a suitable starting material for the rapid and gram-scale synthesis of glycoside **15**, its corresponding Fmoc-protected threonine amino acid **8**, and T_N antigen (**1**). In contrast to our existing systems (Schemes 2a–b),^{7–10} this process can promote the glycosylation with both α - and β -anomers of **16**¹⁶ and only relies on substoichiometric amounts of the nickel catalyst.

While it was known that $\text{Ni}(\text{4-F-PhCN})_4(\text{OTf})_2$ effectively promoted the glycosylation of a wide variety of carbohydrate acceptors with C(2)-*ortho*-(trifluoromethyl)benzylidenamino *N*-phenyl trifluoroacetimidate donors,^{15e-f,17} it was unclear if the reaction of Fmoc-protected threonine amino acid **13** with substrate **16** would proceed with high yield and α -selectivity. Importantly, it was still unclear if the nickel method can be utilized in a large scale preparation of glycosyl amino acid **15** (Scheme 3). We were delighted to find that by employing only 10 mol% $\text{Ni}(\text{4-F-PhCN})_4(\text{OTf})_2$ the coupling reaction reached completion in 12 h at 35 °C to afford the desired product **15** in 74% yield with exclusive α -anomeric selectivity (Scheme 3a). Purification of the glycosyl amino acid **15**, however, was tedious due to closeness in R_f value of the threonine acceptor **13** to the desired product **15**. In the second trial, we glycosylated **13** with *N*-phenyl trifluoroacetimidate donor **14** on a similar scale (Scheme 3b) and obtained a comparable yield and selectivity (63%, α only). The yield in this second run was slightly lower because we tried two different purification methods (manual and automated chromatography) to separate **15** from unreacted threonine donor **13**. Unfortunately, it was not successful. Anticipating that this problem would be exacerbated in a larger scale, we made the threonine acceptor **13** the limiting reagent (Scheme 3c) and isolated 3.77 g of pure product **15** in 66% yield with α -only selectivity.¹⁸ Overall, the results obtained in Scheme 3 have illustrated the high α -selectivity and scalability of the nickel-catalyzed glycosylation reaction under mild and operationally simple conditions.

Further investigation of scope showed that a glycosylation reaction could be realized using 10 mol% of nickel catalyst, $\text{Ni}(\text{4-F-PhCN})_4(\text{OTf})_2$, with other donors and a number of Fmoc-protected threonine amino acids to afford the desired 1,2-*cis*-2-amino glycosides **17** – **21** (Figure 2) in good yields (61 – 86%) with excellent α -selectivity ($\alpha:\beta = 14:1$ – α only). The terminal alkyne of product **18** is capable of conjugating to biorthogonal azide, via click chemistry,¹⁹ for incorporation into a wide variety of biomolecules.²⁰ This alkyne can also conjugate to a linker possessing the azide functionality to form the corresponding polymerizable monomer, which can then undergo ring-opening metathesis polymerization²¹ to generate highly clustered T_N antigens for potential use as antitumor vaccine candidates.²² On the other hand, both glycosyl amino acids **19** and **20** can be further functionalized to

generate the ST_N antigen (**3**, Figure 1). The Cbz-protected threonine amino acid was also compatible with this nickel system, providing the desired glycoside product **21** (Figure 2) in 67% yield as a single α -anomer.

Since the Fmoc-protected GalNAc-threonine amino acid **8** (Scheme 4) is a versatile building block required for SPPS of mucin-type glycopeptides,^{1b} we next investigated the mild conditions for converting glycosyl amino acid **15** into **8**. The previous conditions (2N – 5N HCl, acetone, 25 – 50 °C)¹⁵ for the exchange of C(2)-N-benzylidenamino functionality with *N*-acetyl group to form **22** (Scheme 4) may not be suitable for use in a large scale synthesis. Using the product **15** from Scheme 3c, we found that the benzylidene group could be removed with acetyl chloride (1.6 equiv) in methanol at 25 °C. Subsequent acetylation of the amine salt intermediate provided the desired Fmoc-protected GalNAc-threonine **22** in 70% yield (Scheme 4). One-half of **22** from batch C (Scheme 4) was utilized to synthesize 1.02 g of Fmoc-protected GalNAc-threonine amino acid **8** (97% yield) using Pd(Ph₃P)₄ in THF and NMA at 25 °C for 1 h. Global hydrolysis of the other half of **22** from batch C with sodium hydroxide in methanol provided 0.4 g of the T_N-antigen (**1**) in 82% yield. While a high yield of **1** was obtained, we found these conditions to be insufficient in fully deprotecting Fmoc group.

We hypothesized that addition of triethylamine alongside sodium hydroxide in methanol would facilitate quantitative global deprotection of the intermediate **22** to produce the T_N antigen (**1**). To test our hypothesis, batches A and B of 1,2-*cis*-2-amino glycoside **15** from Scheme 3a and 3b were combined and transformed to 1.18 g of GalNAc-threonine amino acid intermediate **22** (Scheme 5). We are delighted to report that global deprotection of **22** in the presence of triethylamine and sodium hydroxide occurred with almost quantitative yield (99%, Scheme 5).

In summary, we have illustrated a highly α -selective 1,2-*cis*-2-amino glycosylation reaction utilizing substoichiometric amount of Ni(4-F-PhCN)₄(OTf)₂ to mediate the coupling of a number of Cbz- and Fmoc-protected threonine amino acids with C(2)-*ortho*-(trifluoromethyl)benzylideneamino *N*-phenyl trifluoroacetimidate donors. This methodology demonstrates the utility of our catalytic, selective glycosylation method for a gram scale preparation of glycosyl 1,2-*cis*-2-amino acids and their subsequent transformation into the corresponding Fmoc-protected GalNAc-threonine amino acid and T_N antigen. This operationally simple procedure no longer requires utilization of the commonly used C(2)-azido donors, which are often prepared via the potentially explosive diazotransfer reaction. As the scalable, catalytic, and stereoselective synthesis of complex oligosaccharides and glycoconjugates continues to develop, we anticipate that this nickel-catalyzed glycosylation methodology will have an impact on the strategies used for the preparation of biologically active carbohydrate molecules.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Professor Enoch Mensah of Indiana University Southeast for his earlier work on this project. M.S.C. would like to thank the University of Iowa for a Summer Research Fellowship. A portion of this early work is supported the National Institutes of Health (R01 GM098285).

References

1. (a) Herzner H, Reipen T, Schultz M, Kunz H. *Chem Rev.* 2000; 100:4495–4537. [PubMed: 11749356] (b) Grogan MJ, Pratt MR, Marcaurelle LA, Bertozzi CR. *Annu Rev Biochem.* 2002; 71:593–634. [PubMed: 12045107]
2. Ju T, Otto VI, Cummings RD. *Angew Chem Int Ed.* 2011; 50:2–24.
3. Danishefsky SJ, Allen JR. *Angew Chem Int Ed.* 2000; 39:836–863.
4. (a) Springer GF. *Science.* 1984; 224:1198–1206. [PubMed: 6729450] (b) Springer GF. *J Mol Med.* 1997; 75:594–602. [PubMed: 9297627] (c) Desai PR. *Transfus Med Rev.* 2000; 14:312–325. [PubMed: 11055076]
5. (a) Toyokuni T, Dean B, Cai S, Boivin D, Hakomori S, Singhal AK. *J Am Chem Soc.* 1994; 116:395–396. (b) Springer GF, Desai PR, Spencer BD, Tegtmeier H, Carlstedt SC, Scanlan EF. *Cancer Detect Prev.* 1995; 19:374–380. [PubMed: 7553680] (c) Cipolla L, Rescigno M, Leone A, Peri F, La Ferla B, Nicotra F. *Bioorg Med Chem.* 2002; 10:1639–1646. [PubMed: 11886825] (d) Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI. *J Clin Oncol.* 2003; 21:4292–4298. [PubMed: 14645418] (e) Lo-Man R, Vichier-Guerre S, Perraut R, Deriaud E, Huteau V, BenMohamed L, Diop OM, Livingston PO, Bay S, Leclerc C. *Cancer Res.* 2004; 64:4987–4994. [PubMed: 15256473] (f) Keding SJ, Danishefsky SJ. *Proc Natl Acad Sci.* 2004; 101:11937–11942. [PubMed: 15280546] (g) Dziadek S, Hobel A, Schmidt E, Kunz H. *Angew Chem Int Ed.* 2005; 44:7630–7635. (h) Slovin SF, Keding SJ, Ragupathi G. *Immunol Cell Biol.* 2005; 83:418–428. [PubMed: 16033538] (i) Slovin SF, Ragupathi G, Fernandez C, et al. *Cancer Immunol Immunother.* 2007; 56:1921–1930. [PubMed: 17619878] (j) Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons GJ. *Nat Chem Biol.* 2007; 3:663–667. [PubMed: 17767155]
6. (a) Toyokuni T, Singhal AK. *Chem Soc Rev.* 1995; 24:231–242. (b) Pratt MR, Bertozzi CR. *Chem Soc Rev.* 2005; 34:58–68. [PubMed: 15643490]
7. (a) Kaifu R, Osawa T. *Carbohydr Res.* 1977; 58:235–239. [PubMed: 912683] (b) Ratcliffe RM, Baker DA, Lemieux RU. *Carbohydr Res.* 1981; 93:35–41. [PubMed: 6168373] (c) Paulsen H, Holck J-P. *Carbohydr Res.* 1982; 109:89–107. [PubMed: 6817915] (d) Kunz H, Birnbach S. *Angew Chem Int Ed.* 1986; 25:360–362.
8. Cato D, Buskas T, Boons G-J. *J Carbohydr Res.* 2005; 24:503–516.
9. Representative examples of chemical synthesis of T_N antigen (a) Buskas T, Ingale S, Boons GJ. *Glycobiology.* 2006; 16:113R–136R. (b) Kunz H, Birnbach S, Wernig P. *Carbohydr Res.* 1990; 202:207–223. [PubMed: 2224891] (c) Mathieux N, Paulsen H, Meldal M, Bock K. *J Chem Soc Perkin Trans.* 1997; 1:2359. (d) Koeller KM, Smith ME, Wong CH. *Bioorg Med Chem.* 2000; 8:1017–1025. [PubMed: 10882013] (e) Liebe B, Kunz H. *Angew Chem Int Ed.* 1997; 36:618–621. (f) Kuduk SD, Schwarz JB, Chen X-T, Glunz PW, Sames D, Ragupathi G, Livingston PO, Danishefsky SJ. *J Am Chem Soc.* 1998; 120:12474–12485. (g) Elofsson M, Salvador LA, Kihlberg J. *Tetrahedron.* 1997; 53:369–390. (h) Winans KA, King DS, Rao VR, Bertozzi CR. *Biochemistry.* 1999; 38:11700–11710. [PubMed: 10512626] (i) Svarovsky SA, Barchi JJ. *Carbohydr Res.* 2003; 338:1925–1935. [PubMed: 14499569] (j) Elofsson M, Kihlberg J. *Tetrahedron Lett.* 1995; 36:7499–7502. (l) Paulsen H, Rauwald W, Weichert U. *Liebigs Ann Chem.* 1988:75–86. (m) Nakahara Y, Iijima H, Shohei S, Ogawa T. *Tetrahedron Lett.* 1990; 31:6897–6900. (n) Chen XT, Sames D, Danishefsky SJ. *J Am Chem Soc.* 1998; 120:7760–7769.
10. For chemoenzymatic synthesis of T_N antigen, see: (a) Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H. *Cancer Res.* 2010; 70:1306–1313. [PubMed: 20124478] (b) Leppanen A, Mehta P, Ouyang YB, Ju T, Helin J, Moore KL, van Die I, Canfield WM, McEver RP, Cummings RD. *J Biol Chem.* 1999; 274:24838–24848. [PubMed: 10455156]

11. Lemieux RU, Ratcliffe RM. Can J Chem. 1979; 57:1244–1251.
12. Seeberger PH, Roehrig S, Schell P, Wang Y, Christ WJ. Carbohydr Res. 2000; 328:61–69. [PubMed: 11005576]
13. (a) Nyffeler PT, Liang C-H, Koeller KM, Wong C-H. J Am Chem Soc. 2002; 124:10773–10778. [PubMed: 12207533] (b) Orgueira HA, Bartolozzi A, Schell P, Litjens REJN, Palmacci ER, Seeberger PH. Chem Eur J. 2003; 9:140–169. [PubMed: 12506372]
14. Representative recent methods for the synthesis of T_N antigen derivatives, see: (a) Winterfeld GA, Ito Y, Ogawa T, Schmidt RR. Eur J Org Chem. 1999:1167–1171. (b) Winterfeld GA, Schmidt RR. Angew Chem Int Ed. 2001; 40:2654–2657. (c) Corzana F, Busto JH, Jimenez-Oses G, Garcia de Luis M, Asensio JL, Jimenez-Barbero J, Peregrina JM, Avenoza A. J Am Chem Soc. 2007; 129:9458–9467. [PubMed: 17616194] (d) Corzana F, Busto JH, Marcelo F, Garcia de Luis M, Asensio JL, Martin-Santamaria S, Saenz Y, Torres C, Jimenez-Barbero J, Avenoza A, Peregrina JM. Chem Commun. 2011; 47:5319–5321. (e) Kerns RJ, Zha C, Benakli K, Liang Y-Z. Tetrahedron Lett. 2003; 44:8069–8072. (f) Ryan DA, Gin DY. J Am Chem Soc. 2008; 130:15228–15229. [PubMed: 18950157]
15. (a) Mensah EA, Nguyen HM. J Am Chem Soc. 2009; 131:8778–8780. [PubMed: 19496537] (b) Mensah EA, Yu F, Nguyen HM. J Am Chem Soc. 2010; 132:14288–14302. [PubMed: 20860359] (c) McKay MJ, Nguyen HM. ACS Catalysis. 2012; 2:1563–1595. [PubMed: 22924154] (d) Yu F, Nguyen HM. J Org Chem. 2012; 77:7330–7343. [PubMed: 22838405] (e) McConnell MS, Yu F, Nguyen HM. Chem Commun. 2013; 49:4313–4315. (f) McConnell MS, Mensah EA, Nguyen HM. Carbohydr Res. 2013; 381:146–152. [PubMed: 24121123] (g) McKay MJ, Park NH, Nguyen HM. Chem Eur J. 2014; 20:8691–8701. [PubMed: 24905328]
16. We have also previously conducted a control experiment to determine if β -isomer of *N*-phenyl trifluoroacetimidate undergoes isomerization to its corresponding α -isomer prior to the coupling event.^{15f} The β -isomer did not convert to the corresponding α -isomer. As the reaction progressed, the β -isomer converted into the undesired glycal product. This result suggests that *N*-phenyl trifluoroacetimidate donors may react via a different pathway compared to trichloroacetimidate donors under nickel conditions.
17. For the first preparation of *N*-phenyl-trifluoroacetimidate donors see (a) Yu B, Tao H. Tetrahedron Lett. 2001; 42:2405–2407. (b) Cai S, Yu B. Org Lett. 2003; 5:3827–3830. [PubMed: 14535720]
18. The R_f value of donor **16** is significantly different from that of the desired glycoside **15**. See the Supporting Information for a gram-scale and new strategy for direct preparation of glycosyl donor **16**.
19. (a) Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. Angew Chem Int Ed. 2002; 41:2596–2599. (b) Thirumurugan P, Matosiuk D, Jozwiak K. Chem Rev. 2013; 113:4905–4979. [PubMed: 23531040]
20. Sharpless KB, Manetsch R. Exp Opin Drugs Discovery. 2006; 1:525–538.
21. (a) Kolonko EM, Pontrello JK, Mangold SL, Kiessling LL. J Am Chem Soc. 2009; 131:7327–7333. [PubMed: 19469577] (b) Conrad RM, Grubbs RH. Angew Chem, Int Ed. 2009; 48:8328–8330. (c) Clark PM, Dweck JF, Mason DE, Hart CR, Buck SB, Peters EC, Agnew BJ, Hsieh-Wilson LC. J Am Chem Soc. 2008; 130:11576–11577. [PubMed: 18683930] (d) Rawat M, Gama CI, Matson JB, Hsieh-Wilson LC. J Am Chem Soc. 2008; 130:2959–2961. [PubMed: 18275195]
22. (a) Rabuka D, Parthasarathy R, Lee GS, Chen X, Groves JT, Bertozzi CR. J Am Chem Soc. 2007; 129:5462–5471. [PubMed: 17425309] (b) Jeon I, Lee D, Krauss IJ, Danishefsky SJ. J Am Chem Soc. 2009; 131:14337–14344. [PubMed: 19746915]

Figure 1.
Structure of T_N, TF, and ST_N antigens.

Figure 2.
Scope of the reaction with threonine amino acids

Scheme 1.
Previous Methods for Synthesis of T_N Antigen

Scheme 2.

Route to GalNAc-Threonine Residue via Nickel Catalysis

Scheme 3.

Reproducible and Gram-Scale Synthesis of Glycosyl GalNAc-Threonine Compound 15

Scheme 4.

Gram-Scale Synthesis of T_N Antigen and Fmoc-Protected GalNAc-Threonine Amino Acid:
First Conditions

Scheme 5. Gram-Scale Synthesis of the T_N Antigen (1) - Second Conditions